Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients-Reference-Cited by-同舟云学术

Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients

Published:2023-08 Issue: Volume:189 Page:112933
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Persano Mara^ORCID,Rimini Margherita,Tada Toshifumi^ORCID,Suda Goki^ORCID,Shimose Shigeo,Kudo Masatoshi,Cheon Jaekyung^ORCID,Finkelmeier Fabian,Lim Ho Yeong,Presa José,Masi Gianluca^ORCID,Yoo Changhoon,Lonardi Sara,Tovoli Francesco,Kumada Takashi,Sakamoto Naoya,Iwamoto Hideki,Aoki Tomoko,Chon Hong Jae,Himmelsbach Vera,Niizeki Takashi,Montes Margarida,Vivaldi Caterina,Soldà Caterina,Stefanini Bernardo^ORCID,Hiraoka Atsushi,Sho Takuya,Nishida Naoshi,Steup Christoph,Iavarone Massimo,Di Costanzo Giovanni,Marra Fabio,Tamburini Emiliano^ORCID,Cabibbo Giuseppe,Foschi Francesco Giuseppe,Silletta Marianna,Hirooka Masashi,Kariyama Kazuya^ORCID,Tani Joji,Atsukawa Masanori,Takaguchi Koichi^ORCID,Itobayashi Ei,Fukunishi Shinya,Tsuji Kunihiko,Ishikawa Toru^ORCID,Tajiri Kazuto^ORCID,Ochi Hironori,Yasuda Satoshi,Toyoda Hidenori^ORCID,Ogawa Chikara^ORCID,Nishimura Takashi^ORCID,Hatanaka Takeshi^ORCID,Kakizaki Satoru^ORCID,Shimada Noritomo,Kawata Kazuhito,Tada Fujimasa,Ohama Hideko^ORCID,Nouso Kazuhiro,Morishita Asahiro,Tsutsui Akemi,Nagano Takuya,Itokawa Norio,Okubo Tomomi,Arai Taeang,Imai Michitaka,Kosaka Hisashi^ORCID,Naganuma Atsushi^ORCID,Koizumi Yohei,Nakamura Shinichiro,Kaibori Masaki,Iijima Hiroko,Hiasa Yoichi^ORCID,Campani Claudia,Amadeo Elisabeth,Rossari Federico^ORCID,Burgio Valentina,Cascinu Stefano,Scartozzi Mario,Casadei-Gardini Andrea

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference44 articles.

1. Hepatocellular carcinoma;Llovet;Nat Rev Dis Prim,2021

2. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma;Llovet;Nat Cancer,2022

3. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial;Bruix;Lancet,2017

4. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma;Abou-Alfa;N Engl J Med,2018

5. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial;Zhu;Lancet Oncol,2019

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: Multicenter, real‐world study;Hepatology Research;2024-01-19

2. Updates on Systemic Therapy for Hepatocellular Carcinoma;American Society of Clinical Oncology Educational Book;2024-01

3. Radiotherapy following Intrahepatic Progression on Immunotherapy in Advanced Hepatocellular Carcinoma;Journal of Hepatology;2024-01

4. Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?;European Journal of Cancer;2023-11

5. Response to letter entitled Re: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients;European Journal of Cancer;2023-10